3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
157
Lung Neoplasms
73
Small Cell Lung Carcinoma
52
Neoplasms
8
Melanoma
8
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Mesothelioma, Malignant
6
Mesothelioma
6
Colorectal Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Respiratory Tract Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Diseases
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Bronchogenic
3
Bronchial Neoplasms
3
Adenocarcinoma of Lung
3
Interventions
Carboplatin
18
Pemetrexed
10
Paclitaxel
6
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Drug Delivery Systems
2
Docetaxel
2
Bronchoscopy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zipalertinib
1
zimberelimab
1
toripalimab
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lung Diseases
×
durvalumab
×
Thoracic
×
Clear all
NCT06606847
2026-05-15
LADOGA
AstraZeneca
Phase 2
Active not recruiting
30 enrolled
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled